Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer

In many cancers, octreotide acetate (Sandostatin) has been reported to control the diarrhea that can accompany chemotherapy. However, for patients receiving combined chemotherapy and radiation for anal or rectal cancers, the drug proved no better than a placebo in a randomized trial that was published online March 24 in the Journal of the National Cancer Institute.

Read the whole article on Physorg

More from Physorg